AstraZeneca PLC ADR (AZN)

67.40
+0.70(+1.05%)
After Hours
67.68
+0.27(+0.41%)
- Real-time Data
  • Volume:
    5,393,594
  • Day's Range:
    66.63 - 67.40
  • 52 wk Range:
    53.63 - 71.70

AZN Overview

Prev. Close
66.7
Day's Range
66.63-67.4
Revenue
41.49B
Open
66.8
52 wk Range
53.63-71.7
EPS
-0.33
Volume
5,393,594
Market Cap
207.03B
Dividend (Yield)
1.405
(2.08%)
Average Vol. (3m)
7,174,814
P/E Ratio
-
Beta
0.47
1-Year Change
18.47%
Shares Outstanding
1,549,464,013
Next Earnings Date
Jul 28, 2022
What is your sentiment on AstraZeneca ADR?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC ADR News

AstraZeneca PLC ADR Analysis

AstraZeneca PLC ADR Company Profile

AstraZeneca PLC ADR Company Profile

Employees
83100

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company’s marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • did they develop a vaccine that works now or why is thos going up?
    0
    • Valneva
      0
      • why this trash going up?
        3
        • speculation
          0
      • already breakout guy.
        0
        • I would await some further drop based on the below article to come in the near future. The company did not perform well with the vaccine and i opened some short positions if my assumptions are correct.
          0
          • https://moneyweek.com/investments/stocks-and-shares/biotech-stocks/603675/astrazenecas-covid-troubles-could-see-it-pull
            0
            • hold long = big victory ✌
              0
              • Finally it reached $60+.
                0
                • AZN and MRK: Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. Support is strong for the 2 stocks.
                  0
                  • the Delta virus already in USA, but the CDC covered up the truth. in this next 2 weeks, millions of people will get infected, many states may lockdown again.
                    1